KI member Michael Yaffe and his laboratory team report finding, in the May 11 issue of Cell, that staggering the doses of two common cancer drugs dramatically boosts their ability to kill a particularly malignant type of breast cancer cells. Yaffe has been studying the complex cell signaling pathways of cancer cells and the ability of dysfunctional pathways to promote uncontrolled cell growth. He is now working with researchers at Dana Farber Cancer Institute to plan clinical trials of the novel approach.